We drive scientific discovery across a range of health areas
IAVI’s discovery science efforts are focused on identifying and designing new product candidates to address HIV, tuberculosis (TB), antimicrobial resistance (AMR), and emerging infectious diseases (EIDs). These product candidates include vaccines, monoclonal antibodies, and alternative biologics (novel biological products).
Our discovery portfolio is closely linked to IAVI’s Africa and India hubs, and the teams collaborate with IAVI’s clinical development and global access teams. We take a multidisciplinary approach across our research programs and prioritize discovery research that can be translated into products that meet affordability and accessibility targets for global access.
Our discovery programs include HIV vaccine design and development; broadly neutralizing antibodies for HIV prevention, treatment, and cure; vaccine design and monoclonal antibody discovery for AMR and EIDs; as well as pathogen surveillance and data science. IAVI scientists publish their research in high-impact journals and collaborate closely with other scientists across the world.